
|Videos|October 1, 2015
Can Biosimilars Reduce Specialty Spending?
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Closing the Calcium Gap: How Pharmacists Can Guide Patients Toward Better Bone Health
2
COVID-19 Vaccination in Medically Complex Adults
3
Testing categories in practice — clinical conversations
4
The Vaccine Schedule Just Changed Again—Here’s What's Real and What Isn't
5






































































































